BMJ8h
AB0502 CELLULAR AND PROTEOMIC CHANGES FOLLOWING ADMINISTRATION OF PERESOLIMAB, IN A PHASE 2A TRIAL IN RHEUMATOID ARTHRITIS
Background: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease ...
BMJ16h
AB1192 PREVALENCE, RISK FACTORS, AND OUTCOMES OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN CHINESE: A MULTI-CENTRED COHORT STUDY
1 Alice Ho Miu Ling Nethersole Hospital, Department of Medicine, Tai Po, Hong Kong (SAR) 2 The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, ...
BMJ2d
2018 update of the EULAR recommendations for the management of Behçet’s syndrome
Several new treatment modalities with different mechanisms of action have been studied in patients with Behçet’s syndrome (BS). The aim of the current effort was to update the recommendations in the ...
BMJ2d
POS0819 ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS – EXPERIENCES FROM TUEBINGEN IN 3 PATIENTS
1 University Hospital Tuebingen, Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and ...
BMJ3d
POS0803 VUNAKIZUMAB IN ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, SEAMLESS, PHASE 2/3 STUDY
3 The First Affiliated Hospital of Guangxi Medical University, NanNing, China 4 The Second Affiliated Hospital of Guangxi Medical University, NanNing, China 5 The First Affiliated Hospital of ...
BMJ3d
Inequities in access to biologic and synthetic DMARDs across 46 European countries
1 Department of Health Promotion and Education, Maastricht University, School for Public Health and Primary Care (CAPHRI), Maastricht, The Netherlands 2 Department of Rheumatology, Hospital Garcia de ...
BMJ3d
Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study
Objectives The value of biological disease-modifying antirheumatic drugs (bDMARDs) in spondyloarthritis (SpA) is well recognised, but global access to these treatments can be limited due to high costs ...
BMJ3d
Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee
3 Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 4 Department of Rheumatology & Clinical Immunology, University Medical Center ...
BMJ3d
Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis
1 Department of Rheumatology, North Manchester General Hospital and ARC Epidemiology Unit, University of Manchester, Manchester, UK 2 Department of Imaging Science and Biomedical Engineering, ...
BMJ4d
Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort
Objective To assess patient-physician discordance in global assessment of disease activity in early axial spondyloarthritis (axSpA) over time and determinants of discordance. Methods DESIR (Devenir ...
BMJ5d
A prediction rule for the development of arthritis in seropositive arthralgia patients
2 Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands 3 VU Universitiy Medical center, Department of Rheumatology, Amsterdam, The Netherlands ...
BMJ6d
Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis
2 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Montreal, Quebec, Canada Correspondence to Dr Mohit Kapoor, Division of Genetics and Development, The Toronto ...